Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
Affimed hits new 52-week low after Q4 2022 results
Seeking Alpha News (Thu, 23-Mar 1:37 PM ET)
Affimed GAAP EPS of -€0.60, revenue of €41.35M
Seeking Alpha News (Thu, 23-Mar 6:32 AM ET)
Affimed Reports 2022 Financial Results and Operational Progress
Globe Newswire (Thu, 23-Mar 6:30 AM ET)
Affimed FY 2022 Earnings Preview
Seeking Alpha News (Wed, 22-Mar 12:28 PM ET)
Notable earnings before Thursday's open
Seeking Alpha News (Wed, 22-Mar 11:12 AM ET)
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
Globe Newswire (Thu, 16-Mar 6:30 AM ET)
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
Globe Newswire (Tue, 14-Mar 4:30 PM ET)
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
Globe Newswire (Thu, 9-Mar 5:00 AM ET)
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
Globe Newswire (Wed, 22-Feb 6:30 AM ET)
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
Globe Newswire (Tue, 21-Feb 5:00 AM ET)
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.
Affimed N.V. trades on the NASDAQ stock market under the symbol AFMD.
As of March 27, 2023, AFMD stock price climbed to $0.69 with 483,249 million shares trading.
AFMD has a beta of 1.44, meaning it tends to be more sensitive to market movements. AFMD has a correlation of 0.16 to the broad based SPY ETF.
AFMD has a market cap of $103.03 million. This is considered a Micro Cap stock.
Last quarter Affimed N.V. reported $11 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.01.
In the last 3 years, AFMD stock traded as high as $11.74 and as low as $.55.
The top ETF exchange traded funds that AFMD belongs to (by Net Assets): IWM, IWO, IBB, VTWO, SPDW.
AFMD has underperformed the market in the last year with a price return of -84.4% while the SPY ETF lost -10.5%. AFMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.5% and -9.7%, respectively, while the SPY returned +4.0% and +3.2%, respectively.
AFMD support price is $.63 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AFMD stock will trade within this expected range on the day.